Jeffrey Baron, PharmD, BCOP, DPLA, with the Roswell Park Comprehensive Cancer Center, discusses findings from a 12-center retrospective cohort study showing that quizartinib plus intensive chemotherapy was associated with significantly improved 1-year overall survival vs midostaurin plus intensive chemotherapy in patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.